Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Foghorn Therapeutics (FHTX) Non Operating Income (2020 - 2025)

Foghorn Therapeutics (FHTX) has 6 years of Non Operating Income data on record, last reported at $3.2 million in Q2 2025.

  • For Q2 2025, Non Operating Income fell 13.47% year-over-year to $3.2 million; the TTM value through Jun 2025 reached $16.0 million, up 17.61%, while the annual FY2024 figure was $16.1 million, 17.2% up from the prior year.
  • Non Operating Income reached $3.2 million in Q2 2025 per FHTX's latest filing, down from $4.5 million in the prior quarter.
  • Across five years, Non Operating Income topped out at $4.7 million in Q3 2024 and bottomed at $144000.0 in Q1 2021.
  • Average Non Operating Income over 5 years is $2.6 million, with a median of $3.2 million recorded in 2025.
  • Peak YoY movement for Non Operating Income: skyrocketed 9514.29% in 2021, then dropped 13.47% in 2025.
  • A 5-year view of Non Operating Income shows it stood at $2.0 million in 2021, then skyrocketed by 48.59% to $3.0 million in 2022, then increased by 11.27% to $3.3 million in 2023, then skyrocketed by 34.87% to $4.5 million in 2024, then dropped by 29.79% to $3.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Non Operating Income were $3.2 million in Q2 2025, $4.5 million in Q4 2024, and $4.7 million in Q3 2024.